vs
Side-by-side financial comparison of Ametek (AME) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Ametek is the larger business by last-quarter revenue ($2.0B vs $1.2B, roughly 1.7× Jazz Pharmaceuticals plc). Ametek runs the higher net margin — 19.9% vs 17.0%, a 3.0% gap on every dollar of revenue. On growth, Ametek posted the faster year-over-year revenue change (13.4% vs 10.1%). Ametek produced more free cash flow last quarter ($527.3M vs $345.8M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 7.3%).
AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AME vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.2B |
| Net Profit | $398.6M | $203.5M |
| Gross Margin | 36.0% | — |
| Operating Margin | 25.3% | 21.2% |
| Net Margin | 19.9% | 17.0% |
| Revenue YoY | 13.4% | 10.1% |
| Net Profit YoY | 2.9% | 6.5% |
| EPS (diluted) | $1.73 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.9B | $1.1B | ||
| Q2 25 | $1.8B | $1.0B | ||
| Q1 25 | $1.7B | $897.8M | ||
| Q4 24 | $1.8B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.0B | ||
| Q1 24 | $1.7B | $902.0M |
| Q4 25 | $398.6M | $203.5M | ||
| Q3 25 | $371.4M | $251.4M | ||
| Q2 25 | $358.4M | $-718.5M | ||
| Q1 25 | $351.8M | $-92.5M | ||
| Q4 24 | $387.3M | $191.1M | ||
| Q3 24 | $340.2M | $215.1M | ||
| Q2 24 | $337.7M | $168.6M | ||
| Q1 24 | $310.9M | $-14.6M |
| Q4 25 | 36.0% | — | ||
| Q3 25 | 36.3% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.1% | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 36.0% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | 25.3% | 21.2% | ||
| Q3 25 | 25.8% | 5.1% | ||
| Q2 25 | 26.0% | -65.6% | ||
| Q1 25 | 26.3% | -6.2% | ||
| Q4 24 | 26.6% | 17.5% | ||
| Q3 24 | 26.1% | 24.7% | ||
| Q2 24 | 25.8% | 19.5% | ||
| Q1 24 | 24.0% | 7.3% |
| Q4 25 | 19.9% | 17.0% | ||
| Q3 25 | 19.6% | 22.3% | ||
| Q2 25 | 20.2% | -68.7% | ||
| Q1 25 | 20.3% | -10.3% | ||
| Q4 24 | 22.0% | 17.6% | ||
| Q3 24 | 19.9% | 20.4% | ||
| Q2 24 | 19.5% | 16.5% | ||
| Q1 24 | 17.9% | -1.6% |
| Q4 25 | $1.73 | $3.34 | ||
| Q3 25 | $1.60 | $4.08 | ||
| Q2 25 | $1.55 | $-11.74 | ||
| Q1 25 | $1.52 | $-1.52 | ||
| Q4 24 | $1.67 | $2.97 | ||
| Q3 24 | $1.47 | $3.42 | ||
| Q2 24 | $1.45 | $2.49 | ||
| Q1 24 | $1.34 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $458.0M | $1.4B |
| Total DebtLower is stronger | $2.3B | $5.4B |
| Stockholders' EquityBook value | $10.6B | $4.3B |
| Total Assets | $16.1B | $11.7B |
| Debt / EquityLower = less leverage | 0.21× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $458.0M | $1.4B | ||
| Q3 25 | $439.2M | $1.3B | ||
| Q2 25 | $619.7M | $1.2B | ||
| Q1 25 | $399.0M | $1.9B | ||
| Q4 24 | $374.0M | $2.4B | ||
| Q3 24 | $396.3M | $2.2B | ||
| Q2 24 | $396.6M | $1.4B | ||
| Q1 24 | $373.8M | $1.4B |
| Q4 25 | $2.3B | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | $2.1B | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $10.6B | $4.3B | ||
| Q3 25 | $10.5B | $4.0B | ||
| Q2 25 | $10.4B | $3.7B | ||
| Q1 25 | $10.0B | $4.2B | ||
| Q4 24 | $9.7B | $4.1B | ||
| Q3 24 | $9.6B | $4.2B | ||
| Q2 24 | $9.3B | $3.8B | ||
| Q1 24 | $9.0B | $3.7B |
| Q4 25 | $16.1B | $11.7B | ||
| Q3 25 | $16.2B | $11.4B | ||
| Q2 25 | $15.3B | $10.9B | ||
| Q1 25 | $14.9B | $11.5B | ||
| Q4 24 | $14.6B | $12.0B | ||
| Q3 24 | $14.8B | $12.3B | ||
| Q2 24 | $14.8B | $11.4B | ||
| Q1 24 | $14.9B | $11.3B |
| Q4 25 | 0.21× | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | 0.22× | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.3M | $362.5M |
| Free Cash FlowOCF − Capex | $527.3M | $345.8M |
| FCF MarginFCF / Revenue | 26.4% | 28.9% |
| Capex IntensityCapex / Revenue | 2.9% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.47× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $1.7B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.3M | $362.5M | ||
| Q3 25 | $440.9M | $474.6M | ||
| Q2 25 | $359.1M | $88.9M | ||
| Q1 25 | $417.5M | $429.8M | ||
| Q4 24 | $550.0M | $398.6M | ||
| Q3 24 | $487.2M | $398.7M | ||
| Q2 24 | $381.4M | $331.4M | ||
| Q1 24 | $410.2M | $267.2M |
| Q4 25 | $527.3M | $345.8M | ||
| Q3 25 | $420.0M | $459.4M | ||
| Q2 25 | $329.8M | $75.9M | ||
| Q1 25 | $394.5M | $415.9M | ||
| Q4 24 | $498.3M | $385.3M | ||
| Q3 24 | $460.9M | $388.0M | ||
| Q2 24 | $360.0M | $324.3M | ||
| Q1 24 | $382.6M | $260.3M |
| Q4 25 | 26.4% | 28.9% | ||
| Q3 25 | 22.2% | 40.8% | ||
| Q2 25 | 18.5% | 7.3% | ||
| Q1 25 | 22.8% | 46.3% | ||
| Q4 24 | 28.3% | 35.4% | ||
| Q3 24 | 27.0% | 36.8% | ||
| Q2 24 | 20.8% | 31.7% | ||
| Q1 24 | 22.0% | 28.9% |
| Q4 25 | 2.9% | 1.4% | ||
| Q3 25 | 1.1% | 1.3% | ||
| Q2 25 | 1.6% | 1.2% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 2.9% | 1.2% | ||
| Q3 24 | 1.5% | 1.0% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 1.6% | 0.8% |
| Q4 25 | 1.47× | 1.78× | ||
| Q3 25 | 1.19× | 1.89× | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 1.42× | 2.09× | ||
| Q3 24 | 1.43× | 1.85× | ||
| Q2 24 | 1.13× | 1.97× | ||
| Q1 24 | 1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
